Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
200 participants
INTERVENTIONAL
2025-12-20
2030-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Brief medical history and vital signs,
2. Full pulmonary function tests,
3. Proton MRI,
4. 19F(perfluoropropane) MRI, As part of the MRI, participants will inhale or 19F gas as a contrast agent to assess lung ventilation Spirometry will be performed at each visit according to American Thoracic Society (ATS) guidelines using MedGraphics Elite Series (MedGraphics Corporation. St. Paul, MN USA) and/or nDD EasyOne Spirometer (nDD Medical Technologies Inc. Andover, MA USA). Fractional exhaled nitric oxide (FeNO) will be measured using the NIOX VERO® (Circassia Pharmaceuticals Inc., Morrisville, NC, USA). All measurements will be performed at St Joseph's Healthcare London.
They will be placed in the 3T PET/MRI scanner with a coil fitted over their torso and chest. Hearing protection will be provided to muffle the noise produced by the 3D imaging gradient coils. A pulse oximeter lead will be used to monitor heart rate and oxygen saturation. MRI will be performed for up to a period of seven to ten minutes. All imaging will be performed in a "breath-hold" fashion. All participants will have supplemental oxygen provided via nasal cannula at a flow rate of at least two liters per minute during the scanning process. Logs and records of gas exposure will be maintained for every volunteer in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
¹⁹F (perfluoropropane) MRI
Participants will undergo pulmonary function tests, ¹⁹F (perfluoropropane) MRI at the visit.
19F(perfluoropropane) MRI
19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
19F(perfluoropropane) MRI
19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.
2. Provision of written, informed consent prior to any study specific procedures.
3. Males and females aged 18 to 85 years.
4. Participant must be able to perform a breath-hold for 16s.
5. Participant has a BMI between 18 and 40
6. Participant must be able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater)
7. Participants are judged to be in stable health on the basis of medical history
Exclusion Criteria
1. Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
2. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
3. Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
4. Participant is unable to perform spirometry maneuvers.
5. Participant is unable to perform MRI and CT breath-hold maneuvers.
6. Participant has a history of chronic or acute respiratory disease
7. FEV1 \<70%
8. Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)
9. Participant has a daytime room air oxygen saturation ≤ 92% ± 2% while supine
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Joseph's Health Care London
OTHER
Alexei Ouriadov
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexei Ouriadov
PhD, professor, scientist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Joseph's Healthcare London
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hana Serajeddini, MD, FRCPC
Role: primary
Tommy Li
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SJHCF0001
Identifier Type: -
Identifier Source: org_study_id